BiotechTube

Pasireotide

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Cirrhosis

Conditions

Hepatic Cirrhosis, Alcoholism

Trial Timeline

Jul 1, 2008 → —

NCT ID
NCT00698464

About Pasireotide

Pasireotide is a phase 1 stage product being developed by Novartis for Hepatic Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00698464. Target conditions include Hepatic Cirrhosis, Alcoholism.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (8)

NCT IDPhaseStatus
NCT03103009Phase 1Completed
NCT02780882Phase 2Withdrawn
NCT01617733Phase 2Terminated
NCT00698464Phase 1Completed
NCT00434148Phase 3Completed
NCT00446082Phase 1Completed
NCT00171730Phase 2Completed
NCT00171951Phase 2Completed

Competing Products

20 competing products in Hepatic Cirrhosis

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
25
GB1211 + PlaceboComac MedicalPhase 1/2
33
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
28
OlomorasibEli LillyPhase 1
33
SimufilamCassava SciencesPhase 1
25
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
DS-3201bDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
PexidartinibDaiichi SankyoPhase 1
33
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
33
BocidelparAstellas PharmaPhase 1
33
fezolinetantAstellas PharmaPhase 1
33
enzalutamideAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP2215Astellas PharmaPhase 1
33
BPN14770ShionogiPhase 1
33
S-217622ShionogiPhase 1
33
LemborexantEisaiPhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85